[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564590":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":37,"collaborators":10,"id":39,"slug":10,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Fundación EPIC","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Coronary Artery Disease (CAD)",null,[12],"Device: Essential pro",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DEVICE","Essential pro","Patients in whom treatment with (Essential Pro) has been attempted",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"FUNDACION EPIC","CONTACT","0034987225638","iepic@fundacionepic.org",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":10,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Princess Margaret Hospital","RECRUITING","Lai Chi Kok","Hong Kong",{"type":32,"coordinates":33},"Point",[34,35],114.14031,22.3369,{"lat":35,"lon":34},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100564590",false,"NCT06631157","Essential Pro Study ( rEPIC04E-HK )","Essential Pro Post-Market Clinical Follow-up Study","rEPIC04E-HK","Inclusion Criteria:\n\n* Patient treated with Essential Pro according to routine hospital practice and following instructions for use\n* Informed consent signed\n\nExclusion Criteria:\n\n* Not meet inclusion criteria","ALL","18 Years",{"count":49,"type":50},100,"ESTIMATED","OBSERVATIONAL","Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.",[54,55],"Coronary Artery Disease","Ischemic Heart Disease",[57,58,59],"MDR (Medical Device Regulations)","PMCF (Post-Market Clinical Follow-up)","Paclitaxel eluting coronary balloon dilatation catheter","2026-02-12",{"date":62,"type":63},"2026-02-17","ACTUAL",{"date":65,"type":63},"2025-05-15",{"date":67,"type":50},"2026-11-01",{"name":5,"class":6},1]